Investing.com - OncoCyte reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
OncoCyte announced earnings per share of $-0.080 on revenue of $1M. Analysts polled by Investing.com anticipated EPS of $-0.110 on revenue of $1.65M.
OncoCyte shares are down 28.35% from the beginning of the year and are trading at $0.630 , down-from-52-week-high.
OncoCyte shares gained 5.00% in after-hours trade after the report.
OncoCyte follows other major Healthcare sector earnings this month
OncoCyte's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar